Northeastern University · PharmacologyThe Cannabinoid Therapeutics Lab
Alexandros Makriyannis · Boston, Massachusetts
Research Focus
Dr. Alexandros Makriyannis's lab at Northeastern University focuses on understanding the roles of cannabinoid receptors (CB1 and CB2) in treating various health conditions, particularly pain and inflammation. They design and develop innovative drug candidates that selectively modulate these receptors to create therapies with fewer side effects. The research not only explores the structure and function of these receptors but also aims to use this knowledge to identify new treatment options for diseases such as addiction and fibrotic disorders.
cannabinoid receptorsCB1CB2therapeuticsdrug developmentpain managementinflammationfibrosisselective agonistsallosteric modulators
Research Aims
5AIM 01Understand the pharmacological profiles of CB1 and CB2 receptors.
AIM 02Develop selective agonists and antagonists for cannabinoid receptors.
AIM 03Explore new therapeutic candidates for fibrotic and inflammatory disorders.
AIM 04Investigate the signaling pathways of cannabinoid receptors.
AIM 05Create tools for studying endocannabinoid signaling in vivo.
Skills the Lab Values
molecular pharmacologydrug designin vivo testingin vitro assaysliquid chromatography mass spectrometrycomputational modelingcryoelectron microscopypharmaceutical preparationstructure-function analysismutant studies
Output against the department
Publications576top 8% of dept.37th of 462
this lab
most publishedleast published
Citations28ktop 10% of dept.48th of 462
this lab
most citedleast cited
Career totals from OpenAlex, compared against labs that share a department. A department spans everything from one paper to tens of thousands, so bar heights are on a log scale — otherwise the largest lab would flatten every other bar to a line.